The Function of extravascular coagulation factor IX in haemostasis.

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• The majority of clotting factor IX (FIX) is located extravascularly within the subendothelial basement membrane.
• This extravascular location is critical for effective haemostasis.

Purpose of the Study:

• To summarize preclinical data on extravascular FIX and its haemostatic role.
• To discuss clinical observations supporting extravascular FIX function.
• To compare the in vivo binding of BeneFIX® and Alprolix® to extravascular type IV collagen (Col4).

Main Methods:

• Utilized three mouse models of hemophilia: FIX knockout (CRM-), FIXR333Q (CRM+), and FIXK5A (poor Col4 binding).
• Assessed haemostatic competency using a murine saphenous vein bleeding model.
• Reviewed clinical publications for evidence of extravascular FIX activity.

Main Results:

• CRM status significantly impacts FIX recovery and prophylactic efficacy, with CRM+ animals showing a ~5-fold faster decrease in protection.
• Extravascular haemostasis provides a potential explanation for breakthrough bleeding in patients on extended half-life FIX (EHL-FIX) therapies.
• Both BeneFIX® and Alprolix® demonstrated similar binding affinities to Col4 (Kd~20-40 nM) in mice, with dose-dependent recoveries. Alprolix® exhibited a higher concentration of binding sites due to binding to both Col4 and the neonatal Fc receptor.

Conclusions:

• Preclinical and clinical findings confirm the role of extravascular FIX in haemostasis.
• Determining the CRM status of haemophilia B patients is essential for optimizing prophylactic dosing strategies.
• Understanding CRM status can minimize trial-and-error in treatment, thereby reducing patient morbidity.